Nath Bio-Genes (India) growth ratios

·FMCG & RetailChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+22.0%+9.7%+10.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+5.3%−0.1%+2.3%
+5.4%−1.3%+1.9%
+7.9%−2.6%+13.1%
+4.2%−5.6%+15.9%
+6.9%+16.6%+11.0%
+5.6%+5.7%+6.4%
−171.5%−75.0%+83.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATHBIOGEN₹131.40

Nath Bio-Genes (India) Limited

· FMCG & Retail
₹ CrorePeersSARVESHWARINDOUSSUKHJITSKOHINOORAGRITECHREGAALBSHSLGULPOLYMcap ₹250 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.4+9.7+22.0—
EBITDA Growth—+2.3-0.1+5.3—
EBIT Growth—+1.9-1.3+5.4—
Net Income Growth—+13.1-2.6+7.9—
EPS Growth—+15.9-5.6+4.2—
Total Assets Growth—+11.0+16.6+6.9—
Total Equity Growth—+6.4+5.7+5.6—
Cash from Operations Growth—+83.2-75.0-171.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.